13 Facts About Remdesivir

Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences.

Remdesivir was originally developed to treat hepatitis C, and was investigated for Ebola virus disease and Marburg virus infections before being studied as a post-infection treatment for COVID-19.

Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.

Remdesivir is a protide able to diffuse into cells, where it is converted to GS-441524 monophosphate via the actions of esterases and a phosphoamidase ; this in turn is further phosphorylated to its active metabolite triphosphate by nucleoside-phosphate kinases.

Remdesivir is at least partially metabolized by the cytochrome P450 enzymes CYP2C8, CYP2D6, and CYP3A4.

Related searches

Remdesivir can be synthesized in multiple steps from ribose derivatives.

Remdesivir is approved, or authorized for emergency use, to treat COVID-19 in many countries.

Remdesivir has been authorized for emergency use in India, Singapore, and approved for use in Japan, the European Union, the United States, and Australia for people with severe symptoms.

Remdesivir is the first treatment for COVID-19 to be approved by the U S Food and Drug Administration .

Remdesivir received approval from the US Food and Drug Administration in October 2020, for use in adults and children twelve years and older requiring hospitalization for treatment of severe COVID-19 infections.

Remdesivir is the international nonproprietary name while the development code name was GS-5734.

Remdesivir was originally created and developed by Gilead Sciences in 2009, to treat hepatitis C and respiratory syncytial virus .

Remdesivir was approved for medical use in the United States in October 2020.